Immunotherapy With Autologous Dexosomes for Patients With Stage IV Melanoma

A Phase II, Multicenter, Open-Labeled Study of Immunotherapy With Autologous Dexosomes for Patients With Stage IV Melanoma

Status

Suspended

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00042497

Enrollment

Registered

2002-08-01

Start date

2002-07-31

Completion date

Unknown

Last updated

2005-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Melanoma

Brief summary

The objective is to determine the safety and efficacy of dexosome immunotherapy in patients with Stage IV malignant melanoma

Interventions

BIOLOGICALautologous dexosomes loaded with tumor-specific peptides

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients with Stage IV metastatic melanoma with 0-1 prior treatments for metastatic disease. * All patients must have distant skin, subcutaneous, or nodal metastases (M1a) or lung metastases (M1b), measurable disease, normal lactate dehydrogenase levels, and HLA type A1, A2, or B35. * Patients must have adequate organ function and an estimated life expectancy of at least 3 months.

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026